## **Prostate 2023 Case Scenario**

45-year-old male who presented with abnormal DRE, nodule/mass on LT-hand side noted with normal seminal vesicle, with elevated PSA of 14.9 taken on 5/9/2021.

5/9/2021: Prostate core bx

1. Prostate, LT base: prostatic tissue with focal high grade prostatic intraepithelial neoplasia (HGPIN),
2. Prostate, LT mid: adenocarcinoma of prostate. GS= 7(4+3), involving 60% of tissue, 1 out of 2 cores involved by tumor,
3. Prostate, LT apex: adenocarcinoma of prostate. GS= 7(4+3), involving 90% of tissue, 2 out of 2 cores involved by tumor,
4. Prostate, RT base: benign prostatic tissue,
5. Prostate, RT mid: benign prostatic tissue,
6. Prostate RT apex: small fragment suspicious for prostatic adenocarcinoma:

8 cores total taken

5/10/21: MRI pelvis: Lesion in LT mid-gland to apex peripheral zone and transitional zone with features consistent with prostate cancer. No evidence of pelvic lymphadenopathy. No EPE and No SVI identified.

5/18/21: Robotic-assisted total radical prostatectomy

**Procedure:** Radical prostatectomy

**Histologic Type: A**denocarcinoma, mixed acinar and ductal type

**Histologic Grade**

**Grade Group and Gleason Score:** Grade group 2 (Gleason score 3 + 4)

**Percentage of Pattern 4 in Gleason Score 7:** 70%

**Percentage of Pattern 5:** 0%

**Tumor Quantitation:** Carcinoma present on 14 of 20 histologic

sections

**Extraprostatic Extension (EPE):** Not identified

**Urinary Bladder Neck Invasion:** Not identified

**Seminal Vesicle Invasion:** Not identified

**Margins:** Negative for carcinoma

**Treatment Effect on carcinoma:** No known presurgical therapy

**Lymphovascular Invasion:** Not identified

**Regional Lymph Nodes:** No nodes submitted

**Additional Pathologic Findings:** High grade prostatic intraepithelial neoplasia

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Worksheet | | | | | | | | | | | |
| Primary Site |  |  | | | |  | | Clinical Grade | |  | |
| Histology |  |  | | | |  | | Pathological Grade | |  | |
| RLN pos |  | RLN examined | | | |  | | Post Therapy Grade | |  | |
| Laterality |  | | | | | | | | | | |
| LVI |  | | | | | | | | | | |
| Tumor size clinical |  | | | | | | | | | | |
| Tumor size path |  | | | | | | | | | | |
| Tumor size summary |  | | | | | | | | | | |
| Stage Data items | | | | | | | | | | | |
| AJCC Stage | | | | | | | | | | | |
| Clinical T |  | Pathological T | | | |  | | Post-therapy T | |  | |
| cT Suffix |  | pT Suffix | | | |  | | pT Suffix | |  | |
| Clinical N |  | Pathological N | | | |  | | Post-therapy N | |  | |
| cN Suffix |  | pN Suffix | | | |  | | pN Suffix | |  | |
| Clinical M |  | Pathological M | | | |  | | Post-therapy M | |  | |
| Clinical Stage |  | Pathological Stage | | | |  | | Post-therapy Stage | |  | |
|  | |  | | | | | |  | | | |
| Summary Stage 2018 | | | |  | | | | |
| *EOD Primary Tumor* | | | |  | | | | |
| *EOD Lymph Regional Nodes* | | | |  | | | | |
| *EOD Mets* | | | |  | | | | |
| *Prostate Pathologic Extension* | | | |  | | | | |
| SSDI’s | | | | | | | | |
| Gleason Patterns Clinical | | | | |  | | | |
| Gleason Patterns Pathological | | | | |  | | | |
| Gleason Score Clinical | | | | |  | | | |
| Gleason Score Pathological | | | | |  | | | |
| Gleason Tertiary Pattern | | | | |  | | | |
| Number of Cores Positive | | | | |  | | | |
| Number of Cores Examined | | | | |  | | | |
| PSA | | | | |  | | | |
| Treatment | | | | | | | | | | | |
| Dx staging procedure | | |  | | | |  | | | |  |
| Surgery reason no rx | | |  | | | |  | | | |  |
| Surgical Approach at hospital | | |  | | | |  | | | |  |
| Surgery course | | |  | | | |  | | | |  |
| Surgery of primary site | | |  | | | |  | | | |  |
| Scope of RLN surgery | | |  | | | |  | | | |  |
| Surgery to other site | | |  | | | |  | | | |  |
| Cancer Status | | |  | | | |  | | | |  |